UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000052811
Receipt number R000060272
Scientific Title Investigation of the feasibility of measuring electrical conductivity with paper-based microfluidic chips using blood samples
Date of disclosure of the study information 2023/12/01
Last modified on 2024/04/25 15:50:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Development of electrode sensors for body fluid measurement: Investigation of the possibility of measuring electrical conductivity using blood samples

Acronym

Investigation of the feasibility of measuring electrical conductivity with paper-based microfluidic chips using blood samples

Scientific Title

Investigation of the feasibility of measuring electrical conductivity with paper-based microfluidic chips using blood samples

Scientific Title:Acronym

Investigation of the feasibility of measuring electrical conductivity with paper-based microfluidic chips using blood samples

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the possibility of measuring electrical conductivity in human blood samples using paper-based microfluidic chips, which are electrode sensors for measuring body fluids.

Basic objectives2

Others

Basic objectives -Others

To investigate the correlation between blood viscosity measured by paper-based microfluidic chips measurement and blood viscosity calculated based on blood data

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Measurability in blood samples

Key secondary outcomes

1. Correlation between electrical conductivity (viscosity) of whole blood and plasma
2. Correlation between electrical conductivity (viscosity) of whole blood or plasma and whole blood viscosity
3. Correlation between electrical conductivity (viscosity) of whole blood or plasma and blood test values such as glycolipid levels
4. Correlation between electrical conductivity (viscosity) of whole blood or plasma and AGEs score
5. Correlation between electrical conductivity (viscosity) of whole blood or plasma and body measurements
6. Adverse events


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Subjects who are judged as healthy by self-reported health questionnaire
2. Subjects who agree to participate in this study with a written informed consent after receiving sufficient explanation relating to this study

Key exclusion criteria

1. Subjects who have respiratory, gastrointestinal, hepatic/gallbladder/pancreatic, hematologic, renal, endocrine, cardiovascular and/or mental disease
2. Subjects who had a serious injury or surgical history within 12 weeks prior to this study
3. Pre- or post-menopausal women having obvious changes in physical condition
4. Subjects donate either 400ml or 200ml whole blood or blood component within four weeks prior to this study
5. Subjects who are pregnant or lactating, or subjects who expect to be pregnant during this study
6. Subjects who have cognitive disorder or who have possibility of the disorder
7. Subjects who participated and took the study drug in other clinical trials within four weeks prior to this study
8. Subjects who are judges as unsuitable for this study by the principal investigator or subinvestigators

Target sample size

5


Research contact person

Name of lead principal investigator

1st name Yasuji
Middle name
Last name Arimura

Organization

University of Miyazaki

Division name

Health-Care Research Department of the University Hospital's Kiyotake Satellite Branch, Organization for Promotion of Research and Industry-Academic Regional Collaboration, University of Miyazaki

Zip code

889-1692

Address

Kihara5200, Kiyotake, Miyazaki889-1692, Japan

TEL

0985-85-9577

Email

yasuji_arimura@med.miyazaki-u.ac.jp


Public contact

Name of contact person

1st name Yasuji
Middle name
Last name Arimura

Organization

University of Miyazaki

Division name

Health-Care Research Department, University of Miyazaki

Zip code

889-1692

Address

Kihara5200, Kiyotake, Miyazaki889-1692, Japan

TEL

0985-85-9577

Homepage URL


Email

yasuji_arimura@med.miyazaki-u.ac.jp


Sponsor or person

Institute

University of Miyazaki

Institute

Department

Personal name



Funding Source

Organization

Yoshitama Surface Finishing Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

The Kyushu Institute of Technology

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee of University of Miyazaki

Address

Kihara 5200, Kiyotake, Miyazaki 889-1692, Japan

Tel

0985-85-9010

Email

igakubu_kenkyu@med.miyazaki-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

宮崎大学 研究・産学地域連携推進機構 医学部附属病院清武サテライトブランチ ヘルスケア研究部門(宮崎県)
Health-Care Research Department of the University Hospital's Kiyotake Satellite Branch, Organization for Promotion of Research and Industry-Academic Regional Collaboration, University of Miyazaki(Miyazaki)


Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 11 Month 09 Day

Date of IRB

2023 Year 11 Month 21 Day

Anticipated trial start date

2023 Year 12 Month 15 Day

Last follow-up date

2023 Year 12 Month 28 Day

Date of closure to data entry

2024 Year 03 Month 07 Day

Date trial data considered complete

2024 Year 03 Month 07 Day

Date analysis concluded

2024 Year 04 Month 10 Day


Other

Other related information

Study design-Cross-sectional study.
-Items to be measured: Basic information of the participants, Vital signs (Blood Pressure, Heart Rate), Blood test((Hematological tests, biochemical examination of blood), body measurements (height, weight, BMI, abdominal circumference), body composition (muscle mass, extremity skeletal muscle mass, skeletal muscle mass index, fat mass, body fat percentage), visceral fat area, AGEs.
Electrical conductivity and viscosity of whole blood and plasma using paper-based microfluidic chips.


Management information

Registered date

2023 Year 11 Month 16 Day

Last modified on

2024 Year 04 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060272


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name